NOT FOR DISTRIBUTION
Header cover image

United Laboratories International Holdings

Market Cap

HK$11.7b

Last Updated

2021/04/11 10:20 UTC

Data Sources

Company Financials +

Executive Summary

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. More Details


Snowflake Analysis

Flawless balance sheet and good value.

Share Price & News

How has United Laboratories International Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3933 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 3933's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

9.7%

3933

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

-14.0%

3933

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: 3933 underperformed the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: 3933 underperformed the Hong Kong Market which returned 28.6% over the past year.


Shareholder returns

3933IndustryMarket
7 Day9.7%0.8%-1.1%
30 Day3.9%0.7%-1.8%
90 Day24.0%10.0%3.4%
1 Year-13.0%-14.0%23.0%21.2%33.5%28.6%
3 Year-20.1%-22.8%-14.3%-19.1%4.0%-6.9%
5 Year97.0%90.1%79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is United Laboratories International Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 3933 (HK$6.35) is trading below our estimate of fair value (HK$19.97)

Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 3933 is poor value based on its PE Ratio (13.4x) compared to the HK Pharmaceuticals industry average (12x).

PE vs Market: 3933 is poor value based on its PE Ratio (13.4x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: 3933 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: 3933 is good value based on its PB Ratio (1.1x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3933's forecast earnings growth (17.6% per year) is above the savings rate (1.5%).

Earnings vs Market: 3933's earnings (17.6% per year) are forecast to grow slower than the Hong Kong market (18.6% per year).

High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3933's revenue (6.7% per year) is forecast to grow slower than the Hong Kong market (13.3% per year).

High Growth Revenue: 3933's revenue (6.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (11.8%).


Past Performance

How has United Laboratories International Holdings performed over the past 5 years?

57.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3933 has high quality earnings.

Growing Profit Margin: 3933's current net profit margins (8%) are higher than last year (7.6%).


Past Earnings Growth Analysis

Earnings Trend: 3933's earnings have grown significantly by 57.1% per year over the past 5 years.

Accelerating Growth: 3933's earnings growth over the past year (9.6%) is below its 5-year average (57.1% per year).

Earnings vs Industry: 3933 earnings growth over the past year (9.6%) exceeded the Pharmaceuticals industry 2.7%.


Return on Equity

High ROE: 3933's Return on Equity (8.1%) is considered low.


Financial Health

How is United Laboratories International Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 3933's short term assets (CN¥8.2B) exceed its short term liabilities (CN¥4.9B).

Long Term Liabilities: 3933's short term assets (CN¥8.2B) exceed its long term liabilities (CN¥1.5B).


Debt to Equity History and Analysis

Debt Level: 3933's debt to equity ratio (25.7%) is considered satisfactory.

Reducing Debt: 3933's debt to equity ratio has reduced from 74% to 25.7% over the past 5 years.

Debt Coverage: 3933's debt is well covered by operating cash flow (76.2%).

Interest Coverage: 3933's interest payments on its debt are well covered by EBIT (17x coverage).


Balance Sheet


Dividend

What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?

1.50%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 11 2021Ex Dividend DateJul 06 2021Dividend Pay DateJan 01 197018814 days from Ex DividendBuy in the next 85 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 3933's dividend (1.5%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).

High Dividend: 3933's dividend (1.5%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: 3933's dividend payments have been volatile in the past 10 years.

Growing Dividend: 3933's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (20.1%), 3933's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 3933's dividends in 3 years are forecast to be thoroughly covered by earnings (10% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.4yrs

Average board tenure


CEO

United Laboratories International Holdings has no CEO, or we have no data on them.


Board Members

Experienced Board: 3933's board of directors are seasoned and experienced ( 10.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.7%.


Top Shareholders

Company Information

The United Laboratories International Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The United Laboratories International Holdings Limited
  • Ticker: 3933
  • Exchange: SEHK
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$11.686b
  • Shares outstanding: 1.84b
  • Website: https://www.tul.com.cn

Number of Employees


Location

  • The United Laboratories International Holdings Limited
  • 6 Fuk Wang Street
  • Yuen Long Industrial Estate
  • Yuen Long
  • New Territories
  • Hong Kong

Listings


Biography

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through three segm...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:20
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.